Skip to main content

Table 3 Overview of the cfDNA extraction and variant analysis methods methods used by the participants

From: International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA

 

# participants to KRAS analysis (%) (n = 23)

# participants to NRAS analysis (%) (n = 20)

# participants to EGFR analysis (%) (n = 31)

cfDNA extraction method

 QIAamp Circulating Nucleic AcidKit (Qiagen)

14 (60.9)

13 (65.0)

17 (54.8)

 Cobas cfDNA Sample Preparation Kit (Roche)

4 (17.4)

3 (15.0)

8 (25.8)

 MagMAX Cell-Free DNA Isolation Kit (Thermo Fisher Scientific)

3 (13.0)

3 (15.0)

3 (9.7)

 Maxwell® RSC ccfDNA Plasma Kit (Promega)

1 (4.3)

0 (0.0)

1 (3.2)

 Nucleospin Plasma XS (Macherey-Nagel)

1 (4.3)

1 (5.0)

1 (3.2)

 QIAamp DSP DNA Blood Mini Kit (Qiagen) version 2

0 (0.0)

0 (0.0)

1 (3.2)

Variant analysis method

 NGS

13 (56.5)

13 (65.0)

12 (38.7)

 Commercial Kit

4 (17.4)

3 (15.0)

11 (35.5)

 LDT

1 (4.3)

0 (0.0)

1 (3.2)

 BEAMing

1 (4.3)

1 (5.0)

0 (0.0)

 ddPCR

4 (17.4)

3 (15.0)

7 (22.6)

  1. The LDT consisted of a 5’nuclease polymerase-chain reaction (Taqman) with peptide nucleic acid probe. For a detailed breakdown of the used methods see Additional file 2: Table S2. Abbreviations: BEAMing Beads, emulsification, amplification, and magnetics, ddPCR Droplet digital polymerase chain reaction, LDT Labroratory-developed test, NGS Next-generation sequencing